Popular Weight-Loss Drug May Cut Heart Attack Risk by 54%, New Studies Find

New research on tirzepatide, the drug behind Zepbound and Mounjaro, suggests it could significantly lower the risk of major cardiovascular event.
format_indent_decrease
AI Article